US stocks surged on Wednesday, fueled by a slowdown in core inflation and better-than-expected earnings from major banks. The ...
TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00.Stay ...
Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...
There's robust potential in US tech, pharma and Qantas, while red flags exist in a number of ASX companies that make them ...
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.
Investing.com -- Bernstein analysts highlighted a more attractive valuation for Novo Nordisk (NYSE: NVO) following recent ...
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.
Super Micro Computer stock was rising Wednesday. The company has until Feb. 25 to file its delayed earnings statement for the last fiscal year under an agreement with the Nasdaq Stock Market. This ...
Hosted on MSN9h
Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays BullishEli Lilly & Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6% plunge — the worst ...
U.S. stock futures are pointing higher as investors watch for key inflation data today. Nasdaq futures are up 0.3% after the ...
LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback